Evaluation of a public expense-covered gynecologic screening program in Japan 2005-2009

Hiroshi Takagi, Satoshi Ichigo, Kazutoshi Matsunami, Atsushi Imai*

Department of Obstetrics and Gynecology, Matsunami General Hospital, Kasamatsu, Gifu, Japan.
Email: *aimai@matsunami-hsp.or.jp

Received 14 April 2011; revised 31 May 2011; accepted 8 June 2011.

ABSTRACT

Introduction: In Japan, there is free physical check-up programs of cancer screening, by which asymptomatic participants undergo a medical examination at public expense. The present study aims to describe their gynecologic findings and compare them with the literatures reported from general hospitals and self-paid check-up programs. Methods: Medical records of Japanese women, who underwent gynecological examinations at public expense between 2005 and 2009, were retrospectively reviewed. Results: Of the cervical smears from 2850 women aged 21 - 82 years, 33 (1.1%) were classified as dysplastic and malignant changes: 28 of low-grade squamous intraepithelial lesion (LSIL), 3 high-grade squamous intraepithelial lesion (HSIL), 2 atypical squamous cells of undetermined significance (ASC-US). No case of cervical squamous cell carcinoma or adenocarcinoma was found. Ultrasonographic examination detected uterus enlargements and ovary tumors in less than 1% of cases. Most of participants (98%) revealed no gynecologic abnormalities. Conclusion: Annual gynecologic screening and proper follow-up programs even against asymptomatic women may remarkably reduce the probability of (pre)malignant disease.

Keywords: Cervical Smear Screening; Transvaginal Sonography; Gynecologic Check-up; Oncology

1. INTRODUCTION

Cervical intraepithelial neoplasia typically develops into invasive cancer over a 10-year period and apparent cases of rapidly progressive cervical cancer are likely to be among women who have escaped screening and proper follow-up [1-6]. The cervical smear (Papanicolaou, Pap smear) is a routine screening test used for the detection of early cervical abnormalities, namely precancerous dysplastic changes of the uterine cervix [1-6]. Organized screening programs for cervical cancer using the cervical smears have been shown to be effective in decreasing mortality and incidence from the disease [1,7]. The cervical screening is a relatively simple, low cost and non-invasive method. Together with transvaginal ultrasonography for detection of ovarian and uterine tumors, a routine cervical screening reduces the probability of developing gynecological malignant diseases.

In many countries, undergoing cancer screening is not mandatory but voluntary. The level of knowledge and attitude toward screening are related to multiple factors such as ethnicity, place of residence, income, and social-economic status [8-12]. In Japan, there are free physical check-up programs of cancer screening, by which asymptomatic participants undergo a medical examination at public expense. The present study aims to describe their gynecologic findings and compare them with the literatures reported from general hospitals and self-paid check-up programs.

2. METHODS

Between January 2005 and December 2009, 2850 asymptomatic women, age 21-82, visited one of four Kasamatsu City-agreed gynecologic physicians for their physical check-up. The cost was fully covered by the municipal corporation. Gynecologic examinations included routine cancer screening (Papanicolaou test), transvaginal ultrasonography, and pelvic examination by a gynecologist. Cervical and endometrial smears were taken using a speculum and brush and classified into 6 categories: normal, low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), atypical squamous cells of undetermined significance (ASC-US), cervical carcinoma, cervical adenocarcinoma. When classified as inadequate, the participants were soon resubmitted to smear examination. Their records of gynecologic findings were retrospectively reviewed.

3. RESULTS

Table 1 shows the cytologic and ultrasonographic findings
Table 1. Gynecologic findings of participants distributed by age.

<table>
<thead>
<tr>
<th>Age group, years</th>
<th>No. (%)</th>
<th>Cytology</th>
<th>Endometrium</th>
<th>Uterine tumor and abnormalities&lt;sup&gt;1)&lt;/sup&gt;</th>
<th>Ovarian tumor&lt;sup&gt;2)&lt;/sup&gt;</th>
<th>Others&lt;sup&gt;3)&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>LSIL</td>
<td>HSIL</td>
<td>ASC-US</td>
<td>SCC</td>
<td>Hyperplasia/cancer</td>
</tr>
<tr>
<td>20 - 24</td>
<td>26 (0.9)</td>
<td>1 (3.8)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>25 - 29</td>
<td>94 (3.3)</td>
<td>1 (1.1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>30 - 34</td>
<td>282 (9.9)</td>
<td>5 (1.8)</td>
<td>0</td>
<td>1 (0.3)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>35 - 39</td>
<td>400 (14.0)</td>
<td>5 (1.8)</td>
<td>1 (0.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>40 - 44</td>
<td>398 (14.0)</td>
<td>4 (1.3)</td>
<td>1 (0.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>45 - 49</td>
<td>259 (9.1)</td>
<td>3 (1.0)</td>
<td>1 (0.4)</td>
<td>1 (0.4)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>50 - 54</td>
<td>257 (9.1)</td>
<td>3 (1.1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>55 - 59</td>
<td>299 (10.5)</td>
<td>1 (1.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>60 - 64</td>
<td>287 (10.1)</td>
<td>1 (0.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>65 - 69</td>
<td>281 (9.9)</td>
<td>1 (0.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>70 - 74</td>
<td>172 (6.0)</td>
<td>2 (1.2)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>75 - 79</td>
<td>76 (2.7)</td>
<td>1 (1.3)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>&lt;80</td>
<td>19 (0.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>2850 (100)</td>
<td>28 (1.0)</td>
<td>3 (0.1)</td>
<td>2 (&lt;0.1)</td>
<td>13 (0.5)</td>
<td>7 (0.2)</td>
</tr>
</tbody>
</table>

<sup>1)</sup>adenomyosis and uterine myoma (measuring 5 to 9 cm).  <sup>2)</sup>unilobular cyst (measuring 3 to 5 cm) suggestive for benign mass.  <sup>3)</sup>including vaginosis, cervical polyp, prolaps uteri.

Table 1 summarized all other abnormal findings pointed out. No gynecologic abnormality was detected in 98% of cases.

4. DISCUSSION

The cervical smear is a widely used routine test with many benefits, especially in detecting early cervical changes that can be treated to limit dysplastic processes developing into cancer. The previous literatures found squamous intraepithelial lesion (SIL) in 3% - 8% of women aged 20 - 29 years and 1% - 5% of over 30-year age group [1-6]. Of the cervical smear tests on 7585 subjects in our study, 98.2% were negative. The incidence of abnormal cytologic findings (dysplastic changes and cervical cancer) in our study (1.2%) was extremely low compared with other studies performed in developed countries [1-6]. Substantial data point to persistent human papillomavirus (HPV) infection as cervical cancer cause. The mean time between HPV infection and invasive cancer is about 15 years, and within 2 to 4 years of detection 15.5 to 25.5% of low-grade epithelial lesions become high-grade lesions [13-15]. The most frequently sexually transmitted disease (STD) worldwide is HPV infection [16,17]. Societies where sexual activity starts at a young age and where multiple partners are common are at high risk of exposure to HPV than in conservative societies. For example, a study in Jordan, one of the most conservative and religious countries, found that of the smears from 1176 women aged 18 - 70 years, 9 cases (0.8%) were classified as ASC-US and 2 cases (0.2%) were LSIL. Based on our result of city-agreed check-up, as-
symptomatic participants undergo a medical examination at public expense. The cultural tradition and high concern on check-up of our subjects restrict the likelihood of multiple sexual partners. This may explain why very low incidence of dysplastic changes and cervical cancer were found in our study group of women.

Of pelvic mass, uterine myomas and/or adenomyosis are estimated to be present in 20% - 25% or reproductive-age women, indicating that they are one of the most common human neoplasma [18-20]. A myoma does not necessarily produce symptoms, and even very large ones may go undetected by the patient, particularly if she is obese. Symptoms from myomas depend on their location, size and state of presentation; symptoms are present in 35% - 50% of patients with myomas. Ovarian tumors, cystic or solid, are also frequently asymptomatic and undetected by themselves. The diagnosis of these tumors is not usually difficult using ultrasonography at physical check-up. We observed lower frequency of uterine enlargement and ovarian tumors in our subjects.

The present study based on symptom-free population suggested annual gynecologic screening and proper follow-up programs even against asymptomatic women may remarkably reduce the probability of (pre) malignant disease. Since the study sample was shown to be representative population of high-attitude toward screening but non-high income, most of our observations may have important implications in terms of public health.

REFERENCES


